A-674563

• UNSPSC Description:

  A-674563 is an orally active Akt1 inhibitor with a Ki of 11 nM.

• Target Antigen:

  Akt

• Type:

  Reference compound

• Related Pathways:

  PI3K/Akt/mTOR

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/a-674563.html

• Purity:

  99.87

• Solubility:

  DMSO : 83.33 mg/mL (ultrasonic)

• Smiles:

  N[C@@H](CC1=CC=CC=C1)COC2=CC(C3=CC4=C(C=C3)NN=C4C)=CN=C2

• Molecular Weight:

  358.44

• References & Citations:

  [1]Luo Y, et al. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol Cancer Ther, 2005, 4(6), 977-986.|[2]Zhu QS, et al. Soft tissue sarcoma cells are highly sensitive to AKT blockade: a role for p53-independent up-regulation of GADD45 alpha. Cancer Res, 2008, 68(8), 2895-2903.|[3]Zou Y, et al. Pre-clinical assessment of A-674563 as an anti-melanoma agent. Biochem Biophys Res Commun. 2016 Aug 12;477(1):1-8.|[4]Xu L, et al. Concurrent targeting Akt and sphingosine kinase 1 by A-674563 in acute myeloid leukemia cells. Biochem Biophys Res Commun. 2016 Apr 15;472(4):662-8.|[5]Wang A, et al. Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML. Oncotarget. 2016 May 17;7(20):29131-42.Cell Signal. 2023 Jun 9;109:110753.|J Proteome Res. 2018 Oct 5;17(10):3360-3369.|Oncotarget. 2016 May 17;7(20):29131-42. |Aging. 2020 Nov 17;12(22):23114-23128.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  552325-73-2